Predicting response to neoadjuvant therapy in colorectal cancer patients the role of messenger-and micro-rna profiling

Alberto Izzotti, Chiara Ceccaroli, Marta Geretto, Filippo Grillo Ruggieri, Sara Schenone, Emilio Di Maria

Research output: Contribution to journalArticlepeer-review

Abstract

Colorectal cancer patients’ responses to neoadjuvant therapy undergo broad inter-individual variations. The aim of this systematic review is to identify a molecular signature that is predictive of colon cancer downstaging and/or downgrading after neoadjuvant therapy. Among the hundreds analysed in the available studies, only 19 messenger-RNAs (mRNAs) and six micro-RNAs (miRNAs) were differentially expressed in responders versus non-responders in two or more independent studies. Therefore, a mRNA/miRNA signature can be designed accordingly, with limitations caused by the retrospective nature of these studies, the heterogeneity in study designs and the downgrading/downstaging assessment criteria. This signature can be proposed to tailor neoadjuvant therapy regimens on an individual basis.

Original languageEnglish
Article number1652
Pages (from-to)1-25
Number of pages25
JournalCancers
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Biomarkers
  • Colorectal neoplasms
  • Messenger
  • MicroRNA
  • MiRNAs
  • Neoadjuvant therapy
  • RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Predicting response to neoadjuvant therapy in colorectal cancer patients the role of messenger-and micro-rna profiling'. Together they form a unique fingerprint.

Cite this